At a glance
ClinicalIndex Comparison RecordN/ACompleted· 73 enrolled
Drug / intervention
aprepitant +1 moredrug
Likely dose
aprepitant 125 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Prospective Trial of Oral Administration of Aprepitant For Prevention of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis
In Brief
A clinical study evaluating aprepitant and Placebo for Pancreatitis. Completed, enrolled 73 participants across 1 site.
Detailed Summary
The purpose of this study is to determine if giving Aprepitant 4 hours before and for two days after ERCP decreases the risk of developing pancreatitis after ERCP.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatitis
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2007
First PostedAug 2008
Primary CompletionAug 2010
Study CompletionNov 2012
TodayJul 2026
First PostedAug 15, 2008
Enrollment StartAug 1, 2007
Primary CompletionAug 1, 2010
Study CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 17.9 years ago
Interventions
aprepitantdrug
one dose of aprepitant (125 mg PO 4 hours) prior to their ERCP and one dose (80 mg PO) 18 hours after the first dose
Placebodrug
one dose of placebo (125 mg PO 4 hours) prior to their ERCP and one dose (80 mg PO) 18 hours after the first dose